- Open Access
Glycogen synthase kinase-3β inhibition induces nuclear factor-κB-mediated apoptosis in pediatric acute lymphocyte leukemia cells
© Hu et al; licensee BioMed Central Ltd. 2010
- Received: 3 October 2010
- Accepted: 26 November 2010
- Published: 26 November 2010
Molecular therapies that target genetic abnormalities in leukemic cells and their affected signaling pathways have been emerging in pediatric acute lymphoblastic leukemia (ALL). Glycogen synthase kinase-3β (GSK-3β) has recently been found to positively regulate the activity of nuclear factor-κB (NF-κB). Here, we investigated the relationship between GSK-3β inhibition and NF-κB in apoptosis of pediatric primary leukemia cells obtained from 39 newly diagnosed ALL children in China.
Bone marrow mononuclear cells (BMMC) were isolated by density gradient centrifugation from the heparinized aspirates of children with ALL. We used immunofluorescence staining to detect nuclear GSK-3β in these cells. After treatment with chemically distinct GSK-3β inhibitors in vitro, NF-κB transcriptional activity was identified by means of western blotting and electrophoretic mobility shift assay (EMSA). NF-κB-mediated apoptosis was detected by Annexin V-PE/7-AAD double-staining flow cytometry. The expression level of the survivin gene was detected by reverse-transcriptase polymerase chain reaction (RT-PCR).
GSK-3β significantly accumulates in the nuclei of ALL cells than in the nuclei of control cells. Cell death induced by GSK-3β inhibition in ALL cells was mediated by a downregulation of NF-κB p65 transcriptional activity. GSK-3β inhibition significantly decreased the expression of the NF-κB target gene survivin.
These results indicate that inhibition of GSK-3β downregulates the NF-κB activation pathway, leading to suppression of the expression of an NF-κB-regulated gene and promotion of apoptosis in ALL cells in vitro. Furthermore, our findings suggest that GSK-3β or NF-κB is a potential therapeutic target in the treatment of pediatric ALL.
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Pancreatic Cancer Cell
- Electrophoretic Mobility Shift Assay
- Bone Marrow Mononuclear Cell
Acute lymphocytic leukemia (ALL) is the most common malignancy diagnosed in children, and it accounts for approximately one-third of all pediatric cancers. Although contemporary treatments cure more than 80% of children with ALL, some patients require intensive treatment and many patients still develop serious acute and late complications because of the side effects of the treatments . Therefore, new treatment strategies are needed to improve not only the cure rate but also the quality of life of these children .
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase, whose activity is inhibited by a variety of extracellular stimuli including insulin, growth factors, cell specification factors, and cell adhesion [3–5]. Two homologous mammalian GSK-3 isoforms are encoded by different genes, GSK-3α and GSK-3β. Recently, GSK-3 has been recognized as a key component of a diverse range of cellular functions essential for survival . Fibroblasts from GSK-3β-deficient embryos were sensitized to apoptosis and showed reduced nuclear factor-κB (NF-κB) function . Furthermore, it has been shown that GSK-3β is a prosurvival factor in pancreatic tumor cells, partly through its ability to regulate the NF-κB pathway . These findings suggest a role for GSK-3β (but not GSK-3α) in the regulation of NF-κB activation. Recent experimental evidence has suggested that inhibition of GSK-3β abrogates NF-κB binding to its target gene promoters through an epigenetic mechanism and enhances apoptosis in chronic lymphocytic leukemia (CLL) B cells ex vivo . Consequently, inhibition of GSK-3β activity has been proposed to play a role in the regulation of the NF-κB signaling pathway that elicits cellular survival responses.
However, little is currently known about the significance of GSK-3β to pediatric ALL cell survival. ALL initiates and progresses in the bone marrow (BM). In the present study, we demonstrated that GSK-3β accumulates in the nuclei of primitive pediatric ALL cells from the BM. GSK-3β inhibition leads to suppression of NF-κB transcriptional activity and induces apoptosis through the transcriptional downregulation of the survivin gene.
Fresh ALL samples were obtained from 39 children with newly diagnosed acute lymphoblastic leukemia, with 11 normal BM samples as control, in Affiliated Children's Hospital, Chongqing Medical University. The diagnosis of ALL was based on morphology, immunology, cytogenetic, and molecular classification. The informed consent was obtained from parents, guardians, or patients (as appropriate).
Isolation of leukemia cells and cell culture
Bone marrow mononuclear cells (BMMC) were isolated from heparinized aspirates by Ficoll-Hypaque density gradient centrifugation within 24 h after sampling. To remove adherent cells, BMMC were suspended in RPMI 1640 medium supplemented with 20% fetal calf serum (FCS) and incubated in plastic dishes at 37°C for 24 h before collection of nonadherent cells. These ALL cells were then either used immediately for the laboratory studies described below or cryopreserved in RPMI 1640 medium with 20% FCS and 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until use. If necessary, leukemic samples were further enriched to more than 90% leukemic blasts by removing nonmalignant cells with immunomagnetic beads .
Reagents and antibodies
The GSK-3β inhibitors SB216763, and lithium chloride (LiCl) were obtained from Sigma, USA. A 20 mg/ml solution of SB216763 was prepared in dimethyl sulfoxide (DMSO), stored in small aliquots at -20°C, and then thawed and diluted in cell-culture medium as required. LiCl was dissolved in RPMI 1640 and used at final concentrations of 5 and 10 mM. The high-quality fetal bovine serum and RPMI 1640 medium were products of Gibco Company, USA. RNAiso Plus, Reverse Transcription PCR kits, and primers were products of TaKaRa Biotechnology, Dalian, China. DyLight 549-conjugated goat anti-rabbit IgG and Hoechst 33342 were obtained from CWBio, Beijing, China. Antibodies for immunoblot analysis were obtained from the following suppliers: GSK-3β and NF-κB p65 from Cell Signaling Technology, USA; survivin, β-actin, histone, and goat anti-rabbit IgG-horseradish peroxidase (HRP) from Santa Cruz Biotechnology, CA.
Analysis of GSK-3β expression in ALL cells by immunofluorescence microscopy
BMMC that had been attached to glass slides by cytocentrifugation (StatSpin InC, USA) were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.3% Triton X-100 for 10 min at room temperature, and blocked with 3% bovine serum albumin (BSA) for 30 min. The cells were subsequently subjected to immunofluorescence staining to detect GSK-3β expression with the same primary antibody (diluted 1:200) used for immunoblotting. After a rinse in PBS, cells were incubated with secondary DyLight 549-conjugated goat anti-rabbit IgG antibody. Nuclei were counterstained with Hoechst 33342. SlowFade mounting medium was used. Images were acquired using the Leica Application Suite on a fluorescence microscope (Olympus, Japan) equipped with a 40 ×/0.75 oil DIC objective.
Leukemic cells (1 × 107) undergoing different treatments were rinsed with PBS and lysed in buffer. Nuclear/Cytosolic fractionation was performed using nuclear-cytosol extraction kit (KENGEN Biotechnology, Nanjing, China) according to the manufacturer's instructions. Protein sample concentration was quantified by the BCA method and an equal amount (30 μg of cytosolic or nuclear protein extract) of proteins was loaded in each well of a 10% SDS polyacrylamide gel. Cell extracts were separated by polyacrylamide gel electrophoresis (PAGE), and transferred to polyvinylidene difluoride membrane (PVDF). Primary antibodies against GSK-3β, NF-κB p65, survivin, β-actin, and histone were used. HRP-conjugated anti-IgG was used as the secondary antibody. Western blot band intensities were quantified using Quantity One software (Bio-Rad Laboratories, Inc., USA).
Electrophoretic mobility shift assays (EMSA) for NF-κB
Nuclear lysates were prepared and protein concentrations were measured by the BCA protein assay according to the manufacturer's manual. Equivalent amounts of nuclear extract proteins (2 μg) were preincubated in 1 μl of binding buffer for 20 min at room temperature. Then, a biotin-labeled oligonucleotide probe was added, and the reaction mixture was incubated for 20 min at room temperature. For reactions involving competitor oligonucleotides, the unlabeled competitor and the labeled probes were premixed before addition to the reaction mixture. The samples were analyzed on 6.5% acrylamide gels and electrophoresis was carried out at 180 V for 70 min. Gel contents were transferred to binding-membrane, dried, incubated with streptavidin-HRP, and exposed with an intensifying screen.
Reverse-transcriptase polymerase chain reaction analysis (RT-PCR)
Total RNAs were extracted according to the manufacturer's instructions and were reverse-transcribed using the PrimeScript RT reagent Kit (TaKaRa, Dalian, China). Of a 20 μl cDNA reaction, 5 μl was used as template for amplification with the following specific primers. For human survivin forward: 5'-TCCACTGCCCCACTGAGAAC-3' and reverse 5'-TGGCTCCCAGCCTTCCA-3'; for human GAPDH forward: 5'-CAGCGACACCCACTCCTC-3' and reverse 5'-TGAGGTCCACCACCCTGT-3'. The PCR was performed with the first denaturation step at 94°C for 5 min, and 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 30 s, and extension at 72°C for 1 min. The PCR reaction products were detected with gel electrophoresis and ultraviolet transillumination.
BMMC (1 × 106 cells) were exposed to GSK-3β inhibitors or a matched concentration of diluents. After the treatment, cells were rinsed twice in cold PBS, resuspended in binding buffer, and then analyzed for apoptosis level by a PE-labeled Annexin-V/7-AAD assay. These cells were directly analyzed in a FACScan (BD FACS Calibur Co., USA) with a sample size of at least 10,000 cells gated on the basis of forward and side scatter. Storing and processing of data were accomplished using FACScan software.
Results are expressed as mean ± standard deviation. Statistical analysis was conducted using SPSS 15.0 software. Differences between groups were examined for statistical significance using a one-way analysis of variance and Student's t-test; P values less than 0.05 were considered statistically significant.
GSK-3β accumulated in the nucleus of primary ALL cells
Inhibition of GSK-3β suppressed the binding of NF-κB to the DNA in ALL cells
Pharmacologic inhibition of GSK-3β induced apoptosis in ALL cells
GSK-3β inhibitors had no significant effect on cell apoptosis in normal BMMC
To further evaluate whether GSK-3β inhibition specifically induced apoptosis in ALL cells, we examined the effect of GSK-3β inhibitors on normal BMMC. GSK-3β inhibition was previously shown to preserve umbilical cord blood stem cell activity . However, consistent with the localization of GSK-3β in the nuclei of normal BMMC, we found that the number of apoptotic cells in normal BMMC was not significantly changed in the presence or absence of GSK-3β inhibitors after 48 h of treatment (Figure 4; P > 0.05). The results obtained with GSK-3β inhibition in normal progenitors versus ALL cells provide evidence of a significant therapeutic selectivity.
Pharmacologic inhibition of GSK-3β decreased NF-κB-mediated expression of an antiapoptotic molecule in ALL cells
GSK-3β has recently been shown to be a crucial enzymatic regulator of cancer cell survival in human tumorigenesis [14, 15]. GSK-3β protein is known to be overexpressed in human prostate , pancreatic , and colon  carcinomas. Normally, GSK-3β is expressed in the cytoplasm of cells. Recent studies have shown that GSK-3β could shuttle from the cytoplasm to the nucleus in pancreatic cancer cell lines and in most poorly differentiated human pancreatic adenocarcinomas , and in human CLL B cells . In this study, we found aberrant nuclear accumulation of GSK-3β in cells obtained from children with ALL, whereas GSK-3β was not detected in the nucleus of control cells.
GSK-3β transposition was thought to participate in the regulation of gene transcription through the phosphorylation of transcription factors . NF-κB, an important transcription factor also involved in the regulation of cell proliferation, differentiation, and apoptosis, is deregulated in many human tumors [19, 20]. Previous studies have suggested that NF-κB transcriptional activity is regulated by GSK-3β . Genetic depletion of GSK-3β by RNA interference suppresses basal NF-κB transcriptional activity, leading to decreased pancreatic cancer cell proliferation and survival . Recently, it has been demonstrated that GSK-3β positively regulates NF-κB-mediated drug resistance in acute myeloid leukemia (AML) . In this study, we tested ex vivo the effect of 2 chemically distinct small-molecule inhibitors of GSK-3β at subtoxic concentrations: LiCl, a well-known GSK-3β inhibitor, and SB216763, a widely used maleimide-containing GSK-3β inhibitor. Using the pharmacological inhibitors of GSK-3β, we estimated the level of GSK-3β inhibition by detecting the protein levels of GSK-3β in cytosolic and nuclear extracts through western blot assay. In ALL cells, we found that both inhibitors led to depletion of the nuclear pool of GSK-3β, whereas no change was found in the cytoplasm extract. Moreover, we found that GSK-3β inhibition in ALL cells did not prevent NF-κB relocation from the cytoplasm to the nucleus, but the inhibition affected the transcriptional repression of NF-κB, as shown by EMSA analysis. Similar to previous studies , our studies on pediatric ALL cells show that NF-κB can be regulated by GSK-3β at the level of the nuclear transcriptional complex.
The exact mechanism by which GSK-3β affects NF-κB transcriptional activity is still unknown. GSK-3β influences NF-κB-mediated gene transcription in pancreatic cancer cells at a point distal to the IκB kinase complex . Recent data have demonstrated that GSK-3β may contribute to p65/p50 binding to the promoters and transcriptional activation of NF-κB in CLL cells by regulating histone modification . However, the underlying mechanism by which GSK-3β regulates p65 NF-κB binding to target gene promoters has not been defined.
NF-κB is known as an important factor of cancer cell survival in human tumorigenesis . In this report, we found that GSK-3β suppression sensitized ALL cells to NF-κB-mediated apoptosis. Both SB216763 and LiCl have been shown to induce ALL cells apoptosis. In addition, we observed that there is no significant effect on apoptosis induced by GSK-3β inhibitors in control BMMC. A relevant finding was that GSK-3β was not detected in the nucleus of control BMMC but was detected in the nuclei of ALL cells. Taken together, our results provide evidence of GSK-3β as a novel potential therapeutic target in the treatment of ALL.
Survivin, which is known to be regulated by NF-κB , plays a major role in the suppression of apoptosis . Our previous experiments have shown that the expression of the antiapoptotic gene survivin significantly increased in children with newly diagnosed acute leukemia (data not shown). Using malignant cells obtained from children with ALL, we have analyzed the effect of GSK-3β inhibition on NF-κB-dependent gene expression involved in the survival of ALL cells. We found that both SB216763 and LiCl could inhibit the expression of survivin, thereby promoting cell apoptosis.
Our data demonstrated for the first time the involvement of GSK-3β in pediatric ALL cells, and not in adult leukemia cells, although GSK-3β inhibition played a similar role in inducing apoptosis in leukemia cells via in vitro activation of NF-κB. Thus, inhibition of GSK-3β and of its target NF-κB signaling pathway could represent a new promising approach for pediatric ALL therapy.
We thank doctors for providing technical assistance and insightful discussions during the preparation of the manuscript.
- Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006, 354: 166-178. 10.1056/NEJMra052603.View ArticleGoogle Scholar
- Pui CH, Jeha S: New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007, 6: 149-165. 10.1038/nrd2240.View ArticleGoogle Scholar
- Kaidanovich O, Eldar-Finkelman H: The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets. 2002, 6: 555-561. 10.1517/14728220.127.116.115.View ArticleGoogle Scholar
- Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003, 116: 1175-1186. 10.1242/jcs.00384.View ArticleGoogle Scholar
- Zhong W, Kevin SS, Mark M, Obdulio P, Tim CPS, Michael LC: Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. Nature. 2008, 455: 1205-1210. 10.1038/nature07284.View ArticleGoogle Scholar
- Takada Y, Fang X, Jamaluddin MS, Douglas DB, Bharat BA: Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by Tumor Necrosis Factor. J Biol Chem. 2004, 279: 39541-54. 10.1074/jbc.M403449200.View ArticleGoogle Scholar
- Klaus PH, Juan L, Elizabeth AR, Ming ST, Ou J, James RW: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000, 406: 86-90. 10.1038/35017574.View ArticleGoogle Scholar
- Andrei VO, Martin EF, Doris NS, Raul AU, Daniel DB: Glycogen synthase kinase-3β participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65 (6): 2076-2081. 10.1158/0008-5472.CAN-04-3642.View ArticleGoogle Scholar
- Andrei VO, Nancy DB, Martin EF, Neil EK, Daniel DB: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007, 110: 735-742. 10.1182/blood-2006-12-060947.View ArticleGoogle Scholar
- Amy H, Monique LB, Renee XM, Meyling HC, Cheng C, Karin MK, Gritta EJ, Ulrich G, Ulrike BG, William EE, Rob P: The expression of 70 apoptosis genes in relation to lineage, genetic subtype,cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood. 2006, 107: 769-776. 10.1182/blood-2005-07-2930.View ArticleGoogle Scholar
- Matthew PC, Ainsley AC, Darren AC, Stacey LC, John WY, Nigel JP, Oliver LR, Gregory JM, Paul SC, Lynne RC, David M, Murray JB, David H, Robert WW, David GS, Kenneth JM, Alastair DR, Julie CH: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000, 7: 793-803. 10.1016/S1074-5521(00)00025-9.View ArticleGoogle Scholar
- Peters SK, Douglas AM: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci. 1996, 93 (16): 8455-8459. 10.1073/pnas.93.16.8455.View ArticleGoogle Scholar
- Tiffany H, Tracey AO, Robert K, Robert L, Sylvie S, Emma S, Geoff S, Alla D: Glycogen Synthase Kinase-3β Inhibition Preserves Hematopoietic Stem Cell Activity and Inhibits Leukemic Cell Growth. Stem Cell. 2008, 26: 1288-1297. 10.1634/stemcells.2007-0600.View ArticleGoogle Scholar
- Ghosh JC, Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res. 2005, 11: 4580-4588. 10.1158/1078-0432.CCR-04-2624.View ArticleGoogle Scholar
- Abbas S, Andrei O, Zhi WY, Bin Z, Mohammad HM, Daniel DB, Masayoshi M, Yutaka T, Toshinari M: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005, 334: 1365-1373. 10.1016/j.bbrc.2005.07.041.View ArticleGoogle Scholar
- Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. 2004, 23: 7882-7892. 10.1038/sj.onc.1208068.View ArticleGoogle Scholar
- Andrei VO, Martin EF, Vladimir NB, Thomas CS, Suresh TC, Daniel DB: Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006, 12: 5074-5081. 10.1158/1078-0432.CCR-06-0196.View ArticleGoogle Scholar
- Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M: Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-κB activity. J Biol Chem. 2004, 279: 49571-49574. 10.1074/jbc.C400442200.View ArticleGoogle Scholar
- Michael Karin : Nuclear factor-κB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.View ArticleGoogle Scholar
- Véronique Baud, Michael Karin : Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nature. 2009, 8: 33-40. 10.1038/nrd2781.Google Scholar
- Toni FD, Racaud-Sultan C, Chicanne G, Mas MV, Cariven C, Mesange F, Salles JP, Demur C, Allouche M, Payrastre B, Manenti S, Ysebaert L: A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene. 2006, 25: 3113-3122. 10.1038/sj.onc.1209346.View ArticleGoogle Scholar
- Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004, 6: 203-208. 10.1016/j.ccr.2004.09.003.View ArticleGoogle Scholar
- Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, Garcia JF, Lawler M, Piris MA: Expression of the NF-κB targets BCL2 and BIRCS/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005, 206: 123-134. 10.1002/path.1768.View ArticleGoogle Scholar
- Kuzhuvelil BH, Ajaikumar BK, Kwang SA, Preetha A, Sunil K, Sushovan G, Bharat BA: Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood. 2009, 113: 2003-2013. 10.1182/blood-2008-04-151944.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.